[HTML][HTML] Renal allograft fibrosis: biology and therapeutic targets
Renal tubulointerstitial fibrosis is the final common pathway of progressive renal diseases. In
allografts, it is assessed with tubular atrophy as interstitial fibrosis/tubular atrophy (IF/TA).
IF/TA occurs in about 40% of kidney allografts at 3–6 months after transplantation,
increasing to 65% at 2 years. The origin of renal fibrosis in the allograft is complex and
includes donor-related factors, in particular in case of expanded criteria donors, ischemia-
reperfusion injury, immune-mediated damage, recurrence of underlying diseases …
allografts, it is assessed with tubular atrophy as interstitial fibrosis/tubular atrophy (IF/TA).
IF/TA occurs in about 40% of kidney allografts at 3–6 months after transplantation,
increasing to 65% at 2 years. The origin of renal fibrosis in the allograft is complex and
includes donor-related factors, in particular in case of expanded criteria donors, ischemia-
reperfusion injury, immune-mediated damage, recurrence of underlying diseases …